PEPTIDE CORPUS

Gastrointestinal Health; Cognitive & Neuroprotection

Cholecystokinin (CCK)

Last updated

Evidence on file3 human observational studies · 1 animal study · 1 in-vitro study · 4 citations not yet graded
Strongest sourceNCT02445508: Effect of Bile Acid Secretion and Sequestration on GLP-1 Secretion (human observational study)

Dosing on file unverified

CCK-8: 20 ng/kg IV bolus; 1-4 ng/kg/min IV infusion; 16.4-65.6 pmol/kg/hr; CCK-8: 1-4 ng/kg/min IV infusion; 30 pmol/kg/h; 0.02 mg/kg; Diagnostic: 1-4 ng/kg/min for gallbladder contraction

Carried from a source that labels it unverified, and reproduced with that label attached. A record of what is reported, not a recommendation. No citation on this page establishes it.

Literature on file 9

Not graded

4 citations whose study design could not be read from the title. Left ungraded rather than guessed at.

Identity

UniProt
P06307 (precursor)

Also called

  • Cholecystokinin (CCK) (GI)

Caveat on these identifiers

Source files disagreed on evidence tier for this peptide.

Notes unverified prose

Diagnostic use (gallbladder contraction, pancreatic function); Human infusion studies: CCK-8 1-4 ng/kg/min; 1.5 ng/kg/min in older adults; 112 ng/min for 23 min with gastric distension; Diagnostic use (Kinevac®); CCK-8 IV infusions

Not on file 8

8 of the 8 fields we track hold nothing on this record, and each says why. A blank field is a bug; a named absence is a finding.

Each field links to every other record missing the same thing. The full ledger holds 521 gaps across 136 records.